Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Walter and Eliza Hall Institute-inflammatory cytokine signalling-RNA technology-gene therapy-autoimmune disease
- Development stage
- Preclinical
- Lead developer
- WEHI
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
This preclinical-stage therapeutic candidate is an RNA-based gene therapy being developed through a collaboration between the Walter and Eliza Hall Institute (WEHI) and Roche. The program is designed to treat autoimmune diseases by modulating inflammatory cytokine signaling pathways. By utilizing RNA technology to deliver genetic material that can regulate the production or activity of pro-inflammatory cytokines, the therapy aims to restore immune balance and provide a more targeted intervention than broad-spectrum immunosuppressants. The specific cytokines and the exact RNA platform (e.g., mRNA, circRNA, or siRNA) have not been publicly disclosed, but the project represents a significant effort to apply advanced genetic medicine to the field of immunology.
- Other names
- RNA-based gene therapy to modulate inflammatory cytokine signallingWEHI RNA-based gene therapy for autoimmune disease
Beyond the preview
Go deeper on Walter and Eliza Hall Institute-inflammatory cytokine signalling-RNA technology-gene therapy-autoimmune disease.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Walter and Eliza Hall Institute-inflammatory cytokine signalling-RNA technology-gene therapy-autoimmune disease.